Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer

• Rebecca A. Shatsky,
• Hemali Batra-Sharma,
• Teresa Helsten,
• Richard B. Schwab,
• Emily I. Pittman,
• Minya Pu,
• Elizabeth Weihe,
• Emanuela M. Ghia,
• Laura Z. Rassenti,
• Alfredo Molinolo,
• Betty Cabrera,
• James B. Breitmeyer,
• George F. Widhopf II,
• Karen Messer,
• Catriona Jamieson,
• Thomas J. Kipps,
• Barbara A. Parker

Affiliations

Rebecca A. Shatsky

Moores Cancer Center, University of California San Diego

Hemali Batra-Sharma

Moores Cancer Center, University of California San Diego

Teresa Helsten

Moores Cancer Center, University of California San Diego

Richard B. Schwab

Moores Cancer Center, University of California San Diego

Emily I. Pittman

Moores Cancer Center, University of California San Diego

Minya Pu

Moores Cancer Center, University of California San Diego

Elizabeth Weihe

Department of Radiology, University of California San Diego

Emanuela M. Ghia

Moores Cancer Center, University of California San Diego

Laura Z. Rassenti

Moores Cancer Center, University of California San Diego

Alfredo Molinolo

Moores Cancer Center, University of California San Diego

Betty Cabrera

University of California San Diego California Institute for Regenerative Medicine Alpha Clinic

James B. Breitmeyer

Oncternal Therapeutics, Inc.

George F. Widhopf II

Department of Medicine, University of California San Diego

Karen Messer

Moores Cancer Center, University of California San Diego

Catriona Jamieson

Moores Cancer Center, University of California San Diego

Thomas J. Kipps

Moores Cancer Center, University of California San Diego

Barbara A. Parker

Moores Cancer Center, University of California San Diego